drugset / Trial / NCT00575562
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the safety and tolerability of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer.
Timeline
- Start
- 2007-06
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KRN330 | Monoclonal antibody | — | — |